CANDIDATES FOR PTNM

As many as 7 in 10 patients stop taking OAB medication within 6 months.3 PTNM expands treatment options for eligible patients.

VIEW CRITERIA
Clinician holding a clipboard discusses treatment options with patient.

PTNM PROCEDURE

Watch a short animation of the procedure to see how PTNM is delivered with the NURO device.

DIAGNOSIS AND TREATMENT

1 in 6 adults suffers from OAB.4 Help them find a treatment option to restore bladder function and improve quality of life.

SEE GUIDELINES
Play Video PERCUTANEOUS TIBIAL NEUROMODULATION (PTNM) USING THE NURO SYSTEM.

Percutaneous Tibial Neuromodulation (PTNM) using the NURO System.

OAB CARE PATHWAY

Many patients are reluctant to seek treatment for OAB. Share this pathway with patients to help them understand their options.

GO TO PATHWAY
Nuro System

ONLINE LEARNING

Learn how to use the NURO system and understand its value to your practice.

VIEW COURSE DESCRIPTION

*

Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.

While the NURO device was not used in the studies cited here, since it delivers equivalent stimulation therapy as the device used in the studies, a user can expect similar performance


1

Peters, KM, Carrico, DJ, Perez-Marrero, RA et al. Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT Trial. The Journal of Urology. 2010;183:1438-1443.

2

Peters, KM, MacDiarmid, SA, Wooldridge, LS et al. Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Extended-Release Tolterodine: Results From the Overactive Bladder Innovative Therapy Trial. The Journal of Urology. 2009;182(3):1055-1061.

3

Yeaw J, Benner J, Walt JG et al. Comparing adherence and persistence across 6 chronic medication classes. JMCP. 2009:15(9):724-736.

4

Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May; 20(6):327-336.